Empagliflozin in South Asians with type 2 diabetes: Real world data on effects on cardiometabolic parameters, safety and determinants of response to therapy from a diabetes practice in Sri Lanka-Reference-Cited by-同舟云学术

Empagliflozin in South Asians with type 2 diabetes: Real world data on effects on cardiometabolic parameters, safety and determinants of response to therapy from a diabetes practice in Sri Lanka

Published:2023-02 Issue:1 Volume:17 Page:98-104
ISSN:1751-9918
Container-title:Primary Care Diabetes
language:en
Short-container-title:Primary Care Diabetes

Author:

Dissanayake Harsha^ORCID,Dilrukshi Shani^ORCID,Ratnasamy Vithiya,Soysa Pasindu,Samarathunga Thilina,Bandara Prabhath,De Silva Laksara^ORCID,Katulanda Prasad

Publisher

Elsevier BV

Subject

Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine,Family Practice

Reference29 articles.

1. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes. Metab.,2012

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N. Engl. J. Med.,2016

3. Efficacy and safety of empagliflozin for type 2 diabetes mellitus;Zhang;Medicine,2018

4. Empagliflozin improves kidney outcomes in patients with or without heart failure;Butler;Circ.: Heart Fail.,2019

5. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N. Engl. J. Med.,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Effectiveness Among Different Sodium‐Glucose Cotransoporter‐2 Inhibitors According to Underlying Conditions: A Network Meta‐Analysis of Randomized Controlled Trials;Journal of the American Heart Association;2024-01-31

2. Integrating serum pharmacochemistry and network pharmacology to reveal the mechanism of chickpea in improving insulin resistance;Fitoterapia;2024-01